[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647924":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":10,"locations":23,"responsibleParty":56,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":10,"maxAge":10,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Hospital Universitari Vall d'Hebron Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Primary Prevention Cohort",null,"Consecutive inclusion of patients undergoing DOAC therapy",[13],"Other: DOAC Level",{"label":15,"type":10,"description":16,"interventionNames":17},"Secondary Prevention Cohort","Consecutive inclusion of patients with AF who experience ischemic stroke despite direct oral anticoagulant DOACs.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DOAC Level","Testing for plasma DOAC level concentration to determine 'on-therapy' status",[9,15],[24,42],{"facility":25,"status":26,"city":27,"state":27,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Germans Trias University Hospital","RECRUITING","Barcelona","Spain","ES",{"type":31,"coordinates":32},"Point",[33,34],2.15899,41.38879,{"lat":34,"lon":33},[37],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Jesus Juega, MD, PhD.","CONTACT","934651200","jjuegam.germanstrias@gencat.cat",{"facility":43,"status":26,"city":27,"state":27,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":44,"geoPoint":46,"contacts":47},"Vall d'Hebron University Hospital",{"type":31,"coordinates":45},[33,34],{"lat":34,"lon":33},[48,53],{"name":49,"role":39,"phone":50,"phoneExt":51,"email":52},"Jorge Pagola Perez, MD, PhD.","932746000","6364","jorge.pagola@vallhebron.cat",{"name":54,"role":39,"phone":50,"phoneExt":51,"email":55},"Claudia Meza Burgos, Msc.","claudia.meza@vhir.org",{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100647924","risk-score-of-embolism-in-patients-with-af-undergoing-doac-therapy-100647924",false,"NCT07713537","Risk Score of Embolism in Patients With AF Undergoing DOAC Therapy","Risk Score of Embolism in Patients With Atrial Fibrillation (AF) Undergoing Treatment With Direct Oral Anticoagulant (DOAC)","SAFER-DOAC","Inclusion Criteria:\n\n* Patient over 18 years of age\n* History of AD\n* Currently on DOACs.\n* Capacity to understand the study procedures and provide informed consent.\n\nExclusion Criteria:\n\n* Patient with valvular AF (mitral stenosis) or mechanical valve prostheses.\n* Unable to complete a follow-up period of at least 3 months from enrollment.",true,"ALL",{"count":69,"type":70},250,"ESTIMATED","3 Months","OBSERVATIONAL","Acute ischaemic strokes occur despite the use of direct oral anticoagulants (DOACs). Evidence-based scale is necessary to assess ischemic stroke risk in atrial fibrillation (AF) patients.",[75,76],"Atrial Fibrillation (AF)","Ischemic Stroke","2026-07-17",{"date":79,"type":80},"2026-07-20","ACTUAL",{"date":82,"type":80},"2025-01-01",{"date":84,"type":70},"2027-12-31",{"name":5,"class":6},2]